TY - JOUR
T1 - Correcting the cystic fibrosis disease mutant, A455E CFTR
AU - Cebotaru, Liudmila
AU - Rapino, Daniele
AU - Cebotaru, Valeriu
AU - Guggino, William B.
PY - 2014/1/8
Y1 - 2014/1/8
N2 - Cystic fibrosis is caused by more than 1000 mutations, the most common being the ΔF508 mutation. These mutations have been divided into five classes [1], with ΔF508 CFTR in class II. Here we have studied the class V mutation A455E. We report that the mature and immature bands of A455E are rapidly degraded primarily by proteasomes; the short protein half-life of this mutant therefore resembles that of ΔF508 CFTR. A455E could be rescued by treatment of the cells with proteasome inhibitors. Furthermore, co-transfection of A455E with the truncation mutant Δ264 CFTR also rescued the mature C band, indicating that A455E can be rescued by transcomplementation. We found that Δ264 CFTR bound to A455E, forming a bimolecular complex. Treatment with the compound correctors C3 and C4 also rescued A455E. These results are significant because they show that although ΔF508 belongs to a different class than A455E, it can be rescued by the same strategies, offering therapeutic promise to patients with Class V mutations.
AB - Cystic fibrosis is caused by more than 1000 mutations, the most common being the ΔF508 mutation. These mutations have been divided into five classes [1], with ΔF508 CFTR in class II. Here we have studied the class V mutation A455E. We report that the mature and immature bands of A455E are rapidly degraded primarily by proteasomes; the short protein half-life of this mutant therefore resembles that of ΔF508 CFTR. A455E could be rescued by treatment of the cells with proteasome inhibitors. Furthermore, co-transfection of A455E with the truncation mutant Δ264 CFTR also rescued the mature C band, indicating that A455E can be rescued by transcomplementation. We found that Δ264 CFTR bound to A455E, forming a bimolecular complex. Treatment with the compound correctors C3 and C4 also rescued A455E. These results are significant because they show that although ΔF508 belongs to a different class than A455E, it can be rescued by the same strategies, offering therapeutic promise to patients with Class V mutations.
UR - http://www.scopus.com/inward/record.url?scp=84896913799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896913799&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0085183
DO - 10.1371/journal.pone.0085183
M3 - Article
C2 - 24416359
AN - SCOPUS:84896913799
SN - 1932-6203
VL - 9
JO - PloS one
JF - PloS one
IS - 1
M1 - e85183
ER -